Neurocrine director granted 2,567 RSUs

RASTETTER WILLIAM H reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

RASTETTER WILLIAM H reported acquisition or exercise transactions in this Form 4 filing.

Neurocrine Biosciences director William H. Rastetter received a grant of 2,567 Restricted Stock Units (RSUs). Each RSU represents one share of Neurocrine’s common stock when it vests. The award was made at no cash cost per unit and is held as a direct derivative position.

The RSUs will vest in full on May 27, 2027, meaning Rastetter will receive 2,567 common shares on that date if vesting conditions are satisfied. Following this grant, his reported derivative holdings from this award total 2,567 RSUs.

Insider Trade Summary

Grant/Award: 2,567 shares

Grant/Award 1 txn

Insider RASTETTER WILLIAM H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restriced Stock Unit	2,567	$0.00	$0.00

Holdings After Transaction: Restriced Stock Unit — 2,567 contracts (Direct)

Footnotes (2)

1. F1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
2. F2. The RSUs will vest in full on May 27, 2027.

Key Figures

RSUs granted: 2,567 units RSU grant price: $0.0000 per unit Underlying common shares: 2,567 shares +1 more

4 metrics

RSUs granted 2,567 units Restricted Stock Unit award to director on May 27, 2026

RSU grant price $0.0000 per unit Equity compensation grant, no cash exercise cost

Underlying common shares 2,567 shares Each RSU converts into one common share upon vesting

RSU vesting date May 27, 2027 All granted RSUs vest in full on this date

Key Terms

Restricted Stock Unit, RSU, Common Stock, vesting

4 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share..."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share..."

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

Common Stock financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock..."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"The RSUs will vest in full on May 27, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Neurocrine Biosciences (NBIX) disclose in this Form 4 filing?

Neurocrine Biosciences reported a grant of 2,567 Restricted Stock Units to director William H. Rastetter. These RSUs are a stock-based compensation award and will convert into common shares when they fully vest on May 27, 2027, subject to applicable conditions.

How many Neurocrine (NBIX) RSUs were granted to William H. Rastetter?

The filing shows William H. Rastetter was granted 2,567 Restricted Stock Units. Each RSU represents the right to receive one share of Neurocrine’s common stock upon vesting, providing additional equity-based compensation tied directly to the company’s future share performance.

When do the granted RSUs for Neurocrine (NBIX) director Rastetter vest?

The RSUs granted to William H. Rastetter will vest in full on May 27, 2027. On that vesting date, each of the 2,567 Restricted Stock Units is scheduled to convert into one share of Neurocrine Biosciences common stock, assuming vesting requirements are met.

Does William H. Rastetter pay a price for these Neurocrine (NBIX) RSUs?

The RSUs were granted at a stated price of $0.0000 per unit, indicating no cash exercise cost. Instead, they are a form of equity compensation that converts into 2,567 common shares upon vesting, aligning director interests with long-term shareholder value.

How many Neurocrine (NBIX) derivative shares does Rastetter hold after this grant?

After the transaction, the Form 4 shows Rastetter holding 2,567 derivative securities from this RSU award. These are Restricted Stock Units that each correspond to one Neurocrine common share, scheduled to vest and settle into stock on May 27, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 06:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RASTETTER WILLIAM H

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restriced Stock Unit(1)	$0	05/27/2026		A		2,567		(2)	(2)	Common Stock	2,567	$0	2,567	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

2. The RSUs will vest in full on May 27, 2027.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)